Ambiguity
and Discordance
Elmore et al. 2017
0%
ambiguous
Haws et al. 2012
0%
ambiguous
Gerami et al. 2010
0%
ambiguous
Lodha et al. 2008
0%
ambiguous
Brochez et al. 2002
0%
ambiguous
Veenhuizen et al. 1997
0%
ambiguous| Variable |
Discordance between outside pathology and institutional reports (n=588) |
|---|---|
| Any variable | 87% |
| Final diagnosis | 1.8% |
| Breslow thickness | 65.8% |
| Ulceration | 5.1% |
| Regression | 25.8% |
| Angiolymphatic invasion | 2.89% |
| Perineural invasion | 0.68% |
| Microsatellites | 1.19% |
| Mitotic figures | 56% |
Patrawala et al. 2016
These changes led to a shift in AJCC staging of 20% of pathology reports which in turn would change the clinical management for that patient.
Order MyPath® Melanoma
Video Webinar
An introduction to our diagnostic GEP by Castle Biosciences Medical Director Matthew Goldberg, MD.
Quick Links
Expert Opinions in Melanoma
When Is the MyPath Melanoma Test Most Helpful
On-Demand
Educational Programs
